Enblo (enavogliflozin) / Daewoong Pharma, GC Biopharma, M8 Pharma  >>  Phase 4
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Enblo (enavogliflozin) / Daewoong Pharma, GC Biopharma, M8 Pharma
NCT06399835: Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

Recruiting
4
120
RoW
Enavogliflozin, Envlo Tab., Pioglitazone, Actos Tab.
Seoul National University Bundang Hospital, Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes
06/26
12/26
ENRICH-PEF, NCT06350487: The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction

Not yet recruiting
4
154
RoW
SGLT2 inhibitor, SGLT2 inhibitor: Enavogliflozin (Brand names: Envlo tab)
Samsung Medical Center
Heart Failure, Preserved Ejection Fraction
12/25
06/26
ENDEAVOR-HCM, NCT06580717: ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy

Recruiting
4
200
RoW
enavogliflozin 0.3mg, enavogliflozin Placebo
Yonsei University
Nonobstructive Hypertrophic Cardiomyopathy
11/26
11/26
ENAVO-AF, NCT06528262: Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation

Not yet recruiting
4
390
RoW
Enavogliflozin, Placebo
Yonsei University
Atrial Fibrillation
08/26
08/26
ARNI-TAVI, NCT05672836: ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement

Not yet recruiting
4
1040
RoW
Enavogliflozin, Standard-of-Care, Standard-of-Care medical therapy
Duk-Woo Park, MD, CardioVascular Research Foundation, Korea, Daewoong Pharmaceutical Co. LTD.
Aortic Valve Stenosis
12/25
04/26

Download Options